-
Je něco špatně v tomto záznamu ?
Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS)
SS. Bielack, C. Blattmann, A. Borkhardt, M. Csóka, W. Hassenpflug, E. Kabíčková, L. Kager, T. Kessler, C. Kratz, T. Kühne, M. Kevric, T. Lehrnbecher, R. Mayer-Steinacker, V. Mettmann, M. Metzler, P. Reichardt, C. Rossig, B. Sorg, I. von...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- cisplatina terapeutické užití MeSH
- doxorubicin terapeutické užití MeSH
- ifosfamid terapeutické užití MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- methotrexát MeSH
- mladiství MeSH
- nádory kostí * farmakoterapie MeSH
- osteosarkom * farmakoterapie MeSH
- příčina smrti MeSH
- protokoly protinádorové kombinované chemoterapie MeSH
- Check Tag
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
PURPOSE: Most aspects of osteosarcoma have been addressed in detail, but there is no comprehensive analysis of deceased patients and causes of death. METHODS: The database of the Cooperative Osteosarcoma Study Group COSS (1980-03/31/2021; 4475 registered high-grade central osteosarcoma patients) was searched deaths from any cause. Affected patients were analyzed for demographic and baseline variables and disease-status at the time of demise. Deaths from causes other than osteosarcoma were analyzed in detail. RESULTS: A total of 1520 deceased patients were identified (median age (range) at osteosarcoma diagnosis 16 (2-78) years; 908 (59.7%) male, 612 (40.3%) female; primary tumor: extremities 1263 (83.1%), trunk 208 (13.7%), craniofacial 47 (3.1%) (site unknown 2); metastases at registration: absent 1.051 (69.1%), present 466 (30.7%) (3 no data). The median time from diagnosis to death was 2.22 (0.08-32.02) years. 1286 (84.6%) patients succumbed to osteosarcoma (370 without achieving complete remission, 488 first, 428 more than one recurrences), 146 (9.6%) to other, 88 (5.8%) to unknown causes. Chemotherapy-related infections (40), secondary malignancies (39), and perioperative complications (19) were among the most frequent potentially treatment-related causes, and high-dose methotrexate (19), doxorubicin (17), and ifosfamide (15) were the drugs most commonly held responsible. Patients with unknown causes of death had an unusually long median follow-up. CONCLUSION: The major cause of death of patients after osteosarcoma is this malignancy, mostly from one of its multiple relapses. However, almost 10% of fatalities are due to other documented causes. Some of these deaths may be preventable with the knowledge gained from comprehensive analyses such as this.
Innere Medizin 3 Sektion Onkologie Universitätsklinikum Ulm Ulm Germany
Klinika Dětské Hematologie a Onkologie UK 2 LF a FN Motol Prague Czech Republic
Onkologie und Palliativmedizin Helios Klinikum Berlin Buch Berlin Germany
Pädiatrische Hämatologie und Onkologie Medizinische Hochschule Hannover Hannover Germany
Pädiatrische Hämatologie und Onkologie Universitätsklinikum Hamburg Eppendorf Hamburg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032812
- 003
- CZ-PrNML
- 005
- 20230131151602.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2022.09.007 $2 doi
- 035 __
- $a (PubMed)36191386
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bielack, Stefan S $u Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany; Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, Münster, Germany. Electronic address: coss@klinikum-stuttgart.de
- 245 10
- $a Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS) / $c SS. Bielack, C. Blattmann, A. Borkhardt, M. Csóka, W. Hassenpflug, E. Kabíčková, L. Kager, T. Kessler, C. Kratz, T. Kühne, M. Kevric, T. Lehrnbecher, R. Mayer-Steinacker, V. Mettmann, M. Metzler, P. Reichardt, C. Rossig, B. Sorg, I. von Luettichau, R. Windhager, S. Hecker-Nolting
- 520 9_
- $a PURPOSE: Most aspects of osteosarcoma have been addressed in detail, but there is no comprehensive analysis of deceased patients and causes of death. METHODS: The database of the Cooperative Osteosarcoma Study Group COSS (1980-03/31/2021; 4475 registered high-grade central osteosarcoma patients) was searched deaths from any cause. Affected patients were analyzed for demographic and baseline variables and disease-status at the time of demise. Deaths from causes other than osteosarcoma were analyzed in detail. RESULTS: A total of 1520 deceased patients were identified (median age (range) at osteosarcoma diagnosis 16 (2-78) years; 908 (59.7%) male, 612 (40.3%) female; primary tumor: extremities 1263 (83.1%), trunk 208 (13.7%), craniofacial 47 (3.1%) (site unknown 2); metastases at registration: absent 1.051 (69.1%), present 466 (30.7%) (3 no data). The median time from diagnosis to death was 2.22 (0.08-32.02) years. 1286 (84.6%) patients succumbed to osteosarcoma (370 without achieving complete remission, 488 first, 428 more than one recurrences), 146 (9.6%) to other, 88 (5.8%) to unknown causes. Chemotherapy-related infections (40), secondary malignancies (39), and perioperative complications (19) were among the most frequent potentially treatment-related causes, and high-dose methotrexate (19), doxorubicin (17), and ifosfamide (15) were the drugs most commonly held responsible. Patients with unknown causes of death had an unusually long median follow-up. CONCLUSION: The major cause of death of patients after osteosarcoma is this malignancy, mostly from one of its multiple relapses. However, almost 10% of fatalities are due to other documented causes. Some of these deaths may be preventable with the knowledge gained from comprehensive analyses such as this.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a příčina smrti $7 D002423
- 650 12
- $a nádory kostí $x farmakoterapie $7 D001859
- 650 _2
- $a cisplatina $x terapeutické užití $7 D002945
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $7 D000971
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 12
- $a osteosarkom $x farmakoterapie $7 D012516
- 650 _2
- $a ifosfamid $x terapeutické užití $7 D007069
- 650 _2
- $a doxorubicin $x terapeutické užití $7 D004317
- 650 _2
- $a methotrexát $7 D008727
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Blattmann, Claudia $u Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany
- 700 1_
- $a Borkhardt, Arndt $u Kinderklinik, Klinik für Pädiatrische Onkologie u. Hämatologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
- 700 1_
- $a Csóka, Monika $u Semmelweis Egyetem, Budapest, Hungary
- 700 1_
- $a Hassenpflug, Wolf $u Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Kabíčková, Edita $u Klinika Dětské Hematologie a Onkologie UK 2. LF a FN Motol (KDHO), Prague, Czech Republic
- 700 1_
- $a Kager, Leo $u St. Anna Kinderspital, Universitätsklinik für Kinder- und Jugendheilkunde der Medizinischen, Universität Wien and St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
- 700 1_
- $a Kessler, Thorsten $u Klinik für Innere Medizin A: Hämatologie, Hämostaseologie, Onkologie und Pneumologie, Universitätsklinikum Münster, Münster, Germany
- 700 1_
- $a Kratz, Christian $u Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover, Hannover, Germany
- 700 1_
- $a Kühne, Thomas $u Abteilung für Pädiatrische Onkologie/Hämatologie, Universitäts-Kinderspital beider Basel, Basel, Switzerland
- 700 1_
- $a Kevric, Matthias $u Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany
- 700 1_
- $a Lehrnbecher, Thomas $u Klinik für Kinder- und Jugendmedizin, Schwerpunkt Onkologie, Hämatologie und Hämostaseologie, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
- 700 1_
- $a Mayer-Steinacker, Regine $u Innere Medizin III, Sektion Onkologie, Universitätsklinikum Ulm, Ulm, Germany
- 700 1_
- $a Mettmann, Vanessa $u Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany
- 700 1_
- $a Metzler, Markus $u Kinder- und Jugendklinik, Pädiatrische Onkologie und Hämatologie, Universitätsklinikum Erlangen, Erlangen, Germany
- 700 1_
- $a Reichardt, Peter $u Onkologie und Palliativmedizin, Helios Klinikum Berlin-Buch, Berlin, Germany
- 700 1_
- $a Rossig, Claudia $u Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, Münster, Germany
- 700 1_
- $a Sorg, Benjamin $u Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany
- 700 1_
- $a von Luettichau, Irene $u Kinderklinik München Schwabing, Department of Pediatrics and Children's Cancer Research Center, TUM School of Medicine, Technische Universität München, Munich, Germany
- 700 1_
- $a Windhager, Reinhard $u Universitätsklinik für Orthopädie und Unfallchirurgie, Klinische Abteilung für Orthopädie, Medizinische Universität Wien, Vienna, Austria
- 700 1_
- $a Hecker-Nolting, Stefanie $u Cooperative Osteosarcoma Study Group, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 176, č. - (2022), s. 50-57
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36191386 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151558 $b ABA008
- 999 __
- $a ok $b bmc $g 1891507 $s 1184147
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 176 $c - $d 50-57 $e 20220930 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20230120
